国产手术机器人引领者，规模化出海启程 精锋医疗-B(2675) 精锋医疗首次覆盖报告 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | [Table_Invest] 评级： | 增持 | | --- | --- | --- | --- | --- | --- | | 江珅(分析师) | 021-23185638 | jiangshen@gtht.com | S0880525090001 | | | | 赵峻峰(分析师) | 0755-23976629 | zhaojunfeng@gtht.com | S0880519080017 | [当前价格 Table_CurPrice] (港元)： | 58.80 | | 余文心(分析师) | 021-38676666 | yuwenxin@gtht.com | S0880525040111 | | | 本报告导读： 公司是国内手术机器人引领者，通过持续技术革新推动外科手术进步，全球临床手 术量快速爬升，伴随国内销量增长以及海外市场的商业化，公司收入获得快速增长。 [Table_PicQuote] 52周股价走势图 投资要点： 风险提示。临床 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][11][6]. Core Insights - The company is a leader in domestic surgical robotics, driving advancements in surgical procedures through continuous technological innovation. With rapid growth in global clinical surgical volumes, the company is experiencing significant revenue growth alongside increasing domestic sales and commercialization in overseas markets [2][11]. Summary by Sections 1. Domestic Surgical Robotics Leader - The company was founded in May 2017 in Shenzhen and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots. It has developed a "three-in-one" surgical solution combining multi-port, single-port, and remote systems [15][11]. - The company has achieved the highest sales volume among domestic manufacturers in 2024, with 20 units of its multi-port surgical robot sold in China, covering over 220 hospitals across 30 provinces [11][29]. - Revenue is projected to grow from RMB 0.48 billion in 2023 to RMB 1.6 billion in 2024, driven by increased sales and market acceptance of its products [29][30]. 2. Clinical Advantages of Surgical Robots - Surgical robots provide significant clinical benefits, including high precision, stability, and repeatability, which traditional laparoscopic surgeries struggle to achieve. This technology is transforming the landscape of minimally invasive surgeries [38][39]. 3. International Expansion and Sales Growth - The company has successfully entered overseas markets, securing five orders in 2024 and establishing a distribution network across five continents. By the end of 2025, it had signed global sales agreements for 118 units, with 72 units designated for international markets [11][29]. - The company’s internationalization efforts have marked a transition from initial market testing to large-scale expansion [11][29]. 4. Financial Projections - Revenue forecasts for 2025, 2026, and 2027 are RMB 4.32 billion, RMB 8.11 billion, and RMB 12.36 billion, respectively, reflecting substantial growth rates of 170% and 88% in the following years [4][11]. - The company is expected to turn profitable by 2026, with net profit projected to reach RMB 167 million by 2027, following a loss of RMB 219 million in 2024 [4][11]. 5. Management Team and R&D Strength - The management team, led by experienced founders, has built a proprietary technology platform supported by a multidisciplinary R&D team of 265 members. The company holds the highest number of patents in the Chinese surgical robotics sector [20][25]. - The company has established a comprehensive technology platform based on seven proprietary core technology modules, enhancing its competitive edge in the market [26][27].

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) successfully listed on the Hong Kong Stock Exchange on January 8, 2026, with a market capitalization of HKD 22.507 billion and a stock price increase of over 30% on the first day of trading [1][3]. Company Overview - Founded by a couple of PhD graduates in 2017 with an initial capital of CNY 100,000, Precision Medical has grown to a valuation exceeding CNY 10 billion in less than nine years [3][5]. - The company has three approved products, including the multi-port laparoscopic surgical robot, which has been registered for use in various surgical fields and has signed sales agreements for 61 units globally [3][9]. Financial Performance - Precision Medical has reported significant losses, with cumulative losses exceeding CNY 1.1 billion since 2020. The company’s revenues for 2023, 2024, and the first half of 2025 were CNY 48.042 million, CNY 160 million, and CNY 149 million, respectively, while net losses were CNY 213 million, CNY 219 million, and CNY 89.087 million [10][11]. Market Position and Competition - The surgical robot market in China is projected to exceed CNY 100 billion by 2033, with the laparoscopic surgical robot segment being the largest [9]. - Precision Medical faces intense competition, with over 10 similar products already approved in the market, including the well-established Da Vinci system, which has begun local production, thereby increasing competitive pressure on domestic manufacturers [11][12]. Product Development and Strategy - The company has developed a "shared platform" design allowing its multi-port and single-port laparoscopic robots to share the same control console, aiming to reduce costs for hospitals and enhance operational efficiency [12][13]. - Precision Medical is also expanding its training centers globally and has received CE certification for its products, indicating a focus on international market expansion and advanced applications like remote surgery [13].

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) successfully listed on the Hong Kong Stock Exchange on January 8, with an opening increase of 36.45%, reaching HKD 59.00 per share, and a market capitalization of HKD 22.876 billion [1][4]. Company Overview - Precision Medical's IPO was priced at HKD 43.24 per share, with a total issuance of 27.7222 million shares, raising a net amount of HKD 1.117 billion [4]. - The company has received approval for three surgical robot products, including the MP1000 and SP1000, which are already in clinical use across various surgical fields [5][6]. Investment and Market Position - The investor lineup for Precision Medical includes prominent firms such as Sequoia China, Temasek, and UBS AM Singapore, with total subscriptions amounting to USD 75 million [5]. - The company has completed over 12,000 robot-assisted surgeries using the MP1000 and over 2,000 using the SP1000 prior to the IPO [8]. Industry Context - The surgical robot market in China is projected to grow from RMB 2.714 billion in 2019 to RMB 7.184 billion by 2024, with a compound annual growth rate (CAGR) of 21.5% [11]. - The market is competitive, with major players like Intuitive Surgical's da Vinci system holding over 60% of the high-end market share, while domestic companies like MicroPort and Tianzhihang are also emerging [11]. Financial Performance - Precision Medical reported revenues of RMB 48.042 million, RMB 160 million, and RMB 149 million for 2023, 2024, and the first half of 2025, respectively, with corresponding losses of RMB 213 million, RMB 219 million, and RMB 89.087 million [12]. - The company has maintained high R&D expenditures, amounting to RMB 171 million, RMB 226 million, and RMB 97 million during the same periods, which supports product innovation but increases short-term profitability pressure [12].

Group 1 - The company, Jingfeng Medical-B (02675), plans to conduct a global offering of 27.72 million H-shares from December 30, 2025, to January 5, 2026, with a share price of HKD 43.24 per share [1] - The company specializes in advanced surgical robots, having developed products for minimally invasive and non-invasive surgeries, including the multi-port and single-port laparoscopic surgical robots [1] - The company has reported a significant increase in revenue, from RMB 48 million for the year ending December 31, 2023, to RMB 160 million for the year ending December 31, 2024 [2] Group 2 - The company has incurred operating losses during the reporting periods, with net losses of RMB 213 million, RMB 218.5 million, RMB 133 million, and RMB 89.1 million for the respective periods due to R&D expenses [2] - The company has entered cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for shares totaling USD 75 million under certain conditions [3] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations for R&D, commercialization, capacity expansion, and potential strategic acquisitions [4]

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) has passed the listing hearing on the Hong Kong Stock Exchange, with Morgan Stanley and GF Securities as joint sponsors [1] Company Overview - Precision Medical is an advanced surgical robotics company in the medical device industry, focused on the design, development, and manufacturing of surgical robots. The company has three products at different stages of research and development, targeting the market potential of surgical robots, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots for minimally invasive procedures [3] Product Portfolio - The product lineup includes two core self-developed products: the Precision Multi-Port Laparoscopic Surgical Robot and the Precision Single-Port Laparoscopic Surgical Robot. Additionally, the company has the Precision Bronchoscopy Robot, which is not a core product. The Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries across urology, gynecology, general surgery, and thoracic surgery, while the Single-Port Laparoscopic Surgical Robot is used for surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3] Market and Regulatory Achievements - Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots. The company received its first registration approvals from the National Medical Products Administration for these products in December 2022, November 2023, and January 2025, respectively [4] Financial Performance - For the fiscal years ending June 30, 2023, and 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 160 million, respectively. The company incurred losses of approximately RMB 213 million and RMB 219 million for the same periods. The financial data indicates a significant investment in research and development, with R&D expenses of RMB 171.23 million and RMB 226.25 million for the respective years [4][7]